1
|
Hashemi M, Khosroshahi EM, Chegini MK, Abedi M, Matinahmadi A, Hosnarody YSD, Rezaei M, Saghari Y, Fattah E, Abdi S, Entezari M, Nabavi N, Rashidi M, Raesi R, Taheriazam A. miRNAs and exosomal miRNAs in lung cancer: New emerging players in tumor progression and therapy response. Pathol Res Pract 2023; 251:154906. [PMID: 37939448 DOI: 10.1016/j.prp.2023.154906] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/17/2023] [Revised: 10/23/2023] [Accepted: 10/24/2023] [Indexed: 11/10/2023]
Abstract
Non-coding RNAs have shown key roles in cancer and among them, short RNA molecules are known as microRNAs (miRNAs). These molecules have length less than 25 nucleotides and suppress translation and expression. The functional miRNAs are produced in cytoplasm. Lung cancer is a devastating disease that its mortality and morbidity have undergone an increase in recent years. Aggressive behavior leads to undesirable prognosis and tumors demonstrate abnormal proliferation and invasion. In the present review, miRNA functions in lung cancer is described. miRNAs reduce/increase proliferation and metastasis. They modulate cell death and proliferation. Overexpression of oncogenic miRNAs facilitates drug resistance and radio-resistance in lung cancer. Tumor microenvironment components including macrophages and cancer-associated fibroblasts demonstrate interactions with miRNAs in lung cancer. Other factors such as HIF-1α, lncRNAs and circRNAs modulate miRNA expression. miRNAs have also value in the diagnosis of lung cancer. Understanding such interactions can pave the way for developing novel therapeutics in near future for lung cancer patients.
Collapse
Affiliation(s)
- Mehrdad Hashemi
- Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
| | - Elaheh Mohandesi Khosroshahi
- Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
| | - Mehrnaz Kalhor Chegini
- Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
| | - Maryam Abedi
- Department of Pathology, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
| | - Arash Matinahmadi
- Department of Cellular and Molecular Biology, Nicolaus Copernicus University, Torun, Poland
| | - Yasaman Sotodeh Dokht Hosnarody
- Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
| | - Mahdi Rezaei
- Faculty of Medicine, Shahed University, Tehran, Iran
| | - Yalda Saghari
- Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
| | - Eisa Fattah
- School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Soheila Abdi
- Department of Physics, Safadasht Branch, Islamic Azad university, Tehran, Iran
| | - Maliheh Entezari
- Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
| | - Noushin Nabavi
- Department of Urologic Sciences and Vancouver Prostate Centre, University of British Columbia, V6H3Z6 Vancouver, BC, Canada
| | - Mohsen Rashidi
- Department Pharmacology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran; The Health of Plant and Livestock Products Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
| | - Rasoul Raesi
- Department of Health Services Management, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Medical-Surgical Nursing, Mashhad University of Medical Sciences, Mashhad, Iran.
| | - Afshin Taheriazam
- Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Department of Orthopedics, Faculty of medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
| |
Collapse
|
2
|
Sanchez-Cabrero D, Garcia-Guede Á, Burdiel M, Pernía O, Colmenarejo-Fernandez J, Gutierrez L, Higuera O, Rodriguez IE, Rosas-Alonso R, Rodriguez-Antolín C, Losantos-García I, Vera O, De Castro-Carpeño J, Ibanez de Caceres I. miR-124 as a Liquid Biopsy Prognostic Biomarker in Small Extracellular Vesicles from NSCLC Patients. Int J Mol Sci 2023; 24:11464. [PMID: 37511221 PMCID: PMC10380700 DOI: 10.3390/ijms241411464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2023] [Revised: 07/10/2023] [Accepted: 07/12/2023] [Indexed: 07/30/2023] Open
Abstract
Despite advances in non-small cell lung cancer (NSCLC) research, this is still the most common cancer type that has been diagnosed up to date. microRNAs have emerged as useful clinical biomarkers in both tissue and liquid biopsy. However, there are no reliable predictive biomarkers for clinical use. We evaluated the preclinical use of seven candidate miRNAs previously identified by our group. We collected a total of 120 prospective samples from 88 NSCLC patients. miRNA levels were analyzed via qRT-PCR from tissue and blood samples. miR-124 gene target prediction was performed using RNA sequencing data from our group and interrogating data from 2952 NSCLC patients from two public databases. We found higher levels of all seven miRNAs in tissue compared to plasma samples, except for miR-124. Our findings indicate that levels of miR-124, both free-circulating and within exosomes, are increased throughout the progression of the disease, suggesting its potential as a marker of disease progression in both advanced and early stages. Our bioinformatics approach identified KPNA4 and SPOCK1 as potential miR-124 targets in NSCLC. miR-124 levels can be used to identify early-stage NSCLC patients at higher risk of relapse.
Collapse
Affiliation(s)
- Darío Sanchez-Cabrero
- Biomarkers and Experimental Therapeutics in Cancer, IdiPAZ, 28046 Madrid, Spain
- Medical Oncology Department, La Paz University Hospital, 28046 Madrid, Spain
| | - Álvaro Garcia-Guede
- Biomarkers and Experimental Therapeutics in Cancer, IdiPAZ, 28046 Madrid, Spain
- Cancer Epigenetics Laboratory, INGEMM, La Paz University Hospital, 28046 Madrid, Spain
| | - Miranda Burdiel
- Biomarkers and Experimental Therapeutics in Cancer, IdiPAZ, 28046 Madrid, Spain
- Cancer Epigenetics Laboratory, INGEMM, La Paz University Hospital, 28046 Madrid, Spain
| | - Olga Pernía
- Biomarkers and Experimental Therapeutics in Cancer, IdiPAZ, 28046 Madrid, Spain
- Cancer Epigenetics Laboratory, INGEMM, La Paz University Hospital, 28046 Madrid, Spain
| | - Julián Colmenarejo-Fernandez
- Biomarkers and Experimental Therapeutics in Cancer, IdiPAZ, 28046 Madrid, Spain
- Cancer Epigenetics Laboratory, INGEMM, La Paz University Hospital, 28046 Madrid, Spain
| | - Laura Gutierrez
- Biomarkers and Experimental Therapeutics in Cancer, IdiPAZ, 28046 Madrid, Spain
- Medical Oncology Department, La Paz University Hospital, 28046 Madrid, Spain
| | - Oliver Higuera
- Medical Oncology Department, La Paz University Hospital, 28046 Madrid, Spain
| | - Isabel Esteban Rodriguez
- Biomarkers and Experimental Therapeutics in Cancer, IdiPAZ, 28046 Madrid, Spain
- Pathology Department, La Paz University Hospital, 28046 Madrid, Spain
| | - Rocío Rosas-Alonso
- Biomarkers and Experimental Therapeutics in Cancer, IdiPAZ, 28046 Madrid, Spain
- Cancer Epigenetics Laboratory, INGEMM, La Paz University Hospital, 28046 Madrid, Spain
| | - Carlos Rodriguez-Antolín
- Biomarkers and Experimental Therapeutics in Cancer, IdiPAZ, 28046 Madrid, Spain
- Cancer Epigenetics Laboratory, INGEMM, La Paz University Hospital, 28046 Madrid, Spain
| | | | - Olga Vera
- Biomarkers and Experimental Therapeutics in Cancer, IdiPAZ, 28046 Madrid, Spain
- Cancer Epigenetics Laboratory, INGEMM, La Paz University Hospital, 28046 Madrid, Spain
| | - Javier De Castro-Carpeño
- Biomarkers and Experimental Therapeutics in Cancer, IdiPAZ, 28046 Madrid, Spain
- Medical Oncology Department, La Paz University Hospital, 28046 Madrid, Spain
| | - Inmaculada Ibanez de Caceres
- Biomarkers and Experimental Therapeutics in Cancer, IdiPAZ, 28046 Madrid, Spain
- Cancer Epigenetics Laboratory, INGEMM, La Paz University Hospital, 28046 Madrid, Spain
| |
Collapse
|
3
|
Gao S, Liu S, Wei W, Qi Y, Meng F. Advances in targeting of miR‑10‑associated lncRNAs/circRNAs for the management of cancer (Review). Oncol Lett 2023; 25:89. [PMID: 36817057 PMCID: PMC9931999 DOI: 10.3892/ol.2023.13675] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Accepted: 12/30/2022] [Indexed: 01/20/2023] Open
Abstract
With advancements in sequencing technologies, an increasing number of aberrantly expressed long-non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) have been identified in various types of cancer. lncRNAs and circRNAs are now well-established tumor-influencing factors in cancer, driving not only tumor proliferation and invasion, but also cancer progression, drug resistance and metastatic recurrence. The majority of lncRNAs and circRNAs influence cancer progression by targeting microRNAs (miRNAs/miRs). miR-10a and miR-10b, key members of the miR-10 family, have been shown to play important regulatory roles in cell proliferation, differentiation to cancer progression, and development. Manual evaluation and grouping according to different types of competing endogenous RNA and tumor was performed. The review outlined the current state of knowledge on the regulation of miR-10 family-related lncRNAs and circRNAs. The involvement of lncRNAs and circRNAs in the biogenesis, maturation and function of malignant tumors through the miR-10 family, and the key gene targets and signaling cascades that lncRNAs and circRNAs regulate through the miR-10 family were summarized. Based on the findings of this review, it can be hypothesized that lncRNAs and circRNAs targeting the miR-10 family may serve as diagnostic/prognostic markers and/or therapeutic targets for the management of cancer.
Collapse
Affiliation(s)
- Shengyu Gao
- School of Basic Medicine, Jiamusi University, Jiamusi, Heilongjiang 154002, P.R. China,Department of General Surgery I, The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang 154002, P.R. China
| | - Shuang Liu
- School of Basic Medicine, Jiamusi University, Jiamusi, Heilongjiang 154002, P.R. China
| | - Weiwei Wei
- Department of General Surgery I, The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang 154002, P.R. China
| | - Yanxiu Qi
- Department of General Surgery I, The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang 154002, P.R. China
| | - Fanshi Meng
- School of Basic Medicine, Jiamusi University, Jiamusi, Heilongjiang 154002, P.R. China,Department of General Surgery I, The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang 154002, P.R. China,Correspondence to: Professor Fanshi Meng, Department of General Surgery I, The First Affiliated Hospital of Jiamusi University, 348 Dexiang Street, Jiamusi, Heilongjiang 154002, P.R. China, E-mail:
| |
Collapse
|
4
|
Hu Y, Zhao Z, Jin G, Guo J, Nan F, Hu X, Hu Y, Han Q. Long noncoding RNA regulatory factor X3- antisense RNA 1 promotes non-small cell lung cancer via the microRNA-577/signal transducer and activator of transcription 3 axis. Bioengineered 2022; 13:10749-10764. [PMID: 35475457 PMCID: PMC9208461 DOI: 10.1080/21655979.2022.2054910] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Lung cancer is the most frequent malignancy, and non-small cell lung cancer (NSCLC) is its most common pathological type. Molecular targeted therapy has been testified to be effective in intervening in the occurrence and development of malignancies. This study investigates the effect of lncRNA Regulatory Factor X3- antisense RNA 1 (RFX3-AS1) in NSCLC progression. The RFX3-AS1 profile in NSCLC tissues and cells was measured by quantitative reverse transcription PCR (qRT-PCR). The RFX3-AS1 overexpression model was constructed. The cell counting kit-8 (CCK-8) experiment and cell colony formation assay were adopted to test cell viability. The cell apoptosis was determined by flow cytometry (FCM). Cell migration and invasion were monitored by the Transwell assay, and Western blot was implemented to verify the protein profiles of signal transducer and activator of transcription 3 (STAT3), E-cadherin, Vimentin and N-cadherin. In vivo, we validated the impact of RFX3-AS1 overexpression on the NSCLC xenograft mouse model. The targeting relationships between RFX3-AS1 and miR-577, miR-577 and STAT3 were confirmed by the dual-luciferase reporter assay. The results manifested that overexpressing RFX3-AS1 markedly facilitated NSCLC cell proliferation, migration, invasion and epithelial-mesenchymal transition (EMT), and suppressed cell apoptosis. In contrast, miR-577, which was a downstream target of RFX3-AS1, dramatically impeded the malignant biological behaviors of NSCLC cells. STAT3 was a direct target of miR-577, and it was negatively regulated by the latter. STAT3 activation reversed miR-577-mediated anti-tumor roles. In brief, RFX3-AS1 aggravated NSCLC progression by regulating the miR-577/STAT3 axis.
Collapse
Affiliation(s)
- Yanjing Hu
- Department of Thoracic Surgery, The First People's Hospital of Jiangxia District, Wuhan, Hubei, China
| | - Zhi Zhao
- Department of Thoracic Surgery, The First People's Hospital of Jiangxia District, Wuhan, Hubei, China
| | - Gang Jin
- Department of Thoracic Surgery, The First People's Hospital of Jiangxia District, Wuhan, Hubei, China
| | - Junhao Guo
- Department of Thoracic Surgery, The First People's Hospital of Jiangxia District, Wuhan, Hubei, China
| | - Fangyuan Nan
- Department of Thoracic Surgery, The First People's Hospital of Jiangxia District, Wuhan, Hubei, China
| | - Xin Hu
- Department of Thoracic Surgery, The First People's Hospital of Jiangxia District, Wuhan, Hubei, China
| | - Yunsheng Hu
- Department of Thoracic Surgery, The First People's Hospital of Jiangxia District, Wuhan, Hubei, China
| | - Qun Han
- Department of Thoracic Surgery, The First People's Hospital of Jiangxia District, Wuhan, Hubei, China
| |
Collapse
|
5
|
Chai J, Qin L, Zhang G, Hua P, Jin C. Long non-coding MELTF Antisense RNA 1 promotes and prognosis the progression of non-small cell lung cancer by targeting miR-1299. Bioengineered 2022; 13:10594-10604. [PMID: 35441579 PMCID: PMC9161893 DOI: 10.1080/21655979.2022.2063563] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
This paper explored the influence of long non-coding MELTF Antisense RNA 1 (lncRNA MELTF-AS1) on the prognosis of non-small cell lung cancer (NSCLC), and further deepened the understanding of NSCLC. A total of 130 patients with NSCLC participated in current study to detect and compare lncRNA MELTF-AS1 expression in cancer and normal tissues. Kaplan-Meier analysis and log-rank test were chosen to analyze the effect of MELTF-AS1 expression on the survival of patients within 5 years. The correlation between the expression of MELTF-AS1 and the clinical characteristics of NSCLC patients was analyzed, and the prognostic factors of NSCLC were analyzed by multivariate Cox regression. Subsequently, MELTF-AS1 expression in NSCLC cells were detected. The Cell Counting Kit-8 (CCK-8) and Transwell methods were selected to study the proliferation, migration capability and invasion level of NSCLC cells that silencing MELTF-AS1. Through the luciferase activity assay to explore the relationship between MELTF-AS1 and miR-1299, to further understand the effect of silencing MELTF-AS1 on NSCLC. MELTF-AS1 was increased in NSCLC tissues and cells. Silencing MELTF-AS1 suppressed the proliferation ability, migration capability and invasion level of NSCLC cells, which means that low expression of MELTF-AS1 may be more conducive to patient survival. In addition, through luciferase activity analysis and bioinformatics analysis, MELTF-AS1 has a negative effect on miR-1299, and silencing MELTF-AS1 enhanced miR-1299 expression in NSCLC cells. MELTF-AS1 is highly likely to be a promising prognostic biomarker, and associated with the progression of NSCLC.
Collapse
Affiliation(s)
- Jin Chai
- Department of Pharmacy, The Second Hospital of Jilin University, Changchun, Jilin, China
| | - Li Qin
- Department of Thoracic Surgery, The Second Hospital of Jilin University, Changchun, Jilin, China
| | - Guangxin Zhang
- Department of Thoracic Surgery, The Second Hospital of Jilin University, Changchun, Jilin, China
| | - Peiyan Hua
- Department of Thoracic Surgery, The Second Hospital of Jilin University, Changchun, Jilin, China
| | - Chengyan Jin
- Department of Thoracic Surgery, The Second Hospital of Jilin University, Changchun, Jilin, China
| |
Collapse
|